Citalopram associated with complex visual hallucination, a case report

Mowla, Arash; Khosravizadegan, F; Ebrahimi, Abdol Ali; Sabayan, Behnam; Pani, Azadeh

doi:10.1016/j.pnpbp.2009.01.011

Cited by 5 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cases of clinical and excessive dosage, many previous reports have demonstrated that selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline) can cause hallucinations and other psychiatric symptoms. [12][13][14][15][16][17][18][19][20][21] Some previous reports have demonstrated that selective serotonin reuptake inhibitors can lead to these symptoms by causing a pharmacological increase in the dopaminergic neurotransmission that occurs through direct dopamine reuptake blocking or stimulation of the postsynaptic 5-HT 2 and 5-HT 3 receptors. 21,22 This serotonergic neurotransmission function may induce hallucinations.…”

Section: Discussionmentioning

confidence: 99%

Visual Hallucinations During Duloxetine Treatment in a Patient With Major Depressive Disorder

Tomita

Yasui‐Furukori

Kaneko

2013

Clinical Neuropharmacology

View full text Add to dashboard Cite

Duloxetine is a serotonin-noradrenaline reuptake inhibitor that is effective in the treatment of major depressive disorder (MDD) and chronic pain. The safety of duloxetine has been shown by many previous studies. We report a patient who experienced visual hallucinations after taking duloxetine. The patient experienced insomnia and chronic somatic pain. He began taking duloxetine after a diagnosis of MDD and developed visual hallucinations after the duloxetine dose was increased. The hallucinations disappeared after the duloxetine dose was decreased and then stopped; the dose of quetiapine was increased as an alternative. The specific cause of the duloxetine-induced hallucinations is unclear. In addition to other prescription medications and possible interactions with duloxetine, increasing dopamine by blocking noradrenaline transporters or serotonergic neurotransmission function may contribute to the occurrence of hallucinations.

show abstract

Section: Discussionmentioning

confidence: 99%

Visual Hallucinations During Duloxetine Treatment in a Patient With Major Depressive Disorder

Tomita

Yasui‐Furukori

Kaneko

2013

Clinical Neuropharmacology

View full text Add to dashboard Cite

show abstract

“…Although it is unclear whether paroxetine tends to induce nightmares, any drugs associated with norepinephrine, serotonin, or dopamin can induce nightmares 3 . Indeed, there are a number of reports suggesting the hallucinogenic potential of SSRIs 4–20 . A number of patients who have taken SSRIs combined with other neuroactive drugs or have had organic brain dysfunction have presented with hallucinations 4,5,7–10,15–19 .…”

Section: Discussionmentioning

confidence: 99%

A case of serial nightmares and oneiroid state under paroxetine for senile depression

Kobayashi

Yamauchi

2012

Psychogeriatrics

View full text Add to dashboard Cite

We report on rare side effects of paroxetine. A 67‐year‐old female patient who had been suffering from prolonged depression for over a year but had not received appropriate treatment was administered 20‐mg paroxetine daily. However, the patient required hospital admission after 16 days because of behavioural disturbances and delusions that she was being chased by evil persons from a religious group. The delusions were ultimately confirmed to be serial nightmares and an oneiroid state. The nightmares gradually disappeared following discontinuation of paroxetine. The Adverse Drug Reaction Probability Scale showed a score of 6 (probable). Reports on paroxetine‐induced nightmares are rare, and there is a possibility that, in this case, parexetine caused the nightmares in association with depression and assumed underlying brain dysfunction due to ageing.

show abstract

“…However, when prescribing SSRIs, it is important to keep in mind the risk of developing hallucinations, including [49]: 1) visual hallucinations associated with sertraline [50]; 2) complex visual hallucinations associated with venlafaxine [51,52]; 3) visual hallucinations and psychotic symptoms during the treatment of SSRIs involving the sigma receptors of the brain [53,54]; 4) visual hallucinations during the treatment of SSRIs and other ADs [55]; 5) visual and auditory hallucinations induced by paroxetine [56,57]; 6) visual and auditory hallucinations, delusions induced by citalopram and escitalopram, described in young patients [58][59][60], as well as in patients of other age groups [61].…”

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia

Novitsky

Sousa

Asadullin

et al. 2021

jour

View full text Add to dashboard Cite

The purpose of this review is to analyze approaches to the treatment of depressive and negative disorders in schizophrenia in terms of their level of efficacy and safety. Materials and Methods: A search was conducted for full-text articles published over the last 10 years in PubMed, Springer, Wiley Online Library, Taylor & Francis Online, APA PsycInfo, CORE, Science Direct, and eLIBRARY.RU databases. Several articles published previously to this period were also included into the review due to their high scientific value. Results: Our review suggests that antidepressants (ADs) are effective medications and they can be prescribed to correct depressive disorders and negative symptoms in patients with schizophrenia when used in combination with antipsychotics (АPs). However, when administering ADs and АPs combinations, it is important to consider the safety profile of these combinations as well as their tolerance. Negative symptoms of schizophrenia, including those induced by a number of АP, are less amenable to correction by АDs monotherapy, which requires a long period of АPs (on average - 8 weeks), which can be limited in the real life of the patient outside the hospital. Current approaches to the therapy of depressive disorders in patients suffering from schizophrenia vary from country to country. However, most of АDs used in clinical psychiatric practice are widely used in the comorbid state under consideration. Conclusion: The efficacy and safety of АDs of the different classes considered in this review depends on their mechanisms of action, duration of admission, type of АPs taken, and specific clinical situation (acute depressive disorder, major depressive episode, or chronic depressive episode). Most promising in clinical practice are serotonin–norepinephrine reuptake inhibitors (SNRIs) and dual ADs. The use of tricyclic antidepressants (TCAs) is limited due to a higher risk of adverse drug reactions (ADRs). The use of most selective serotonin reuptake inhibitors (SSRIs) is limited due to the risk of aggravation of hallucinations (this risk being higher for patients with visual hallucinations, and lower for those with auditory hallucinations) and\or iatrogenic psychosis. These ADRs may probably occur in patients suffering from schizophrenia due to their ideal "poor metabolizer" pharmacogenetic profile, since most of the drugs considered in this review have hepatic metabolism.

show abstract

Citalopram associated with complex visual hallucination, a case report

Cited by 5 publications

References 11 publications

Visual Hallucinations During Duloxetine Treatment in a Patient With Major Depressive Disorder

Visual Hallucinations During Duloxetine Treatment in a Patient With Major Depressive Disorder

A case of serial nightmares and oneiroid state under paroxetine for senile depression

Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia

Contact Info

Product

Resources

About